Abstract
Background: HER2 receptor amplification or overexpression represents an important driver in 7-34% of cases of GC, playing a relevant role in cell growth, survival and differentiation. In HER2 positive GC, trastuzumab, a humanized antibody against HER2, when combined with 5FU/capecitabine and cisplatin, improves median overall survival. Nevertheless, primary and acquired resistance to the treatment eventually develops.